Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH05033
REVIEW
Contents Vol 2(4)

HIV and increased risk of cardiovascular diseases

Satyajit Das
+ Author Affiliations
- Author Affiliations

Department of GU & HIV Medicine, University Hospitals Coventry & Warwickshire, Stoney Stanton Road, Coventry, UK. Email: satyajit.das@coventrypct.nhs.uk

Sexual Health 2(4) 219-221 https://doi.org/10.1071/SH05033
Submitted: 1 June 2005  Accepted: 5 September 2005   Published: 16 November 2005

Abstract

Highly active antiretroviral therapy (HAART) has significantly increased the survival rate of patients with HIV. However, abnormalities of lipid and insulin metabolism have been recognised and there is an increasing prevalence of fat redistribution, frank diabetes and hyperlipidaemia in HIV-infected patients receiving HAART. Several observational studies have described associations between HIV infection, HAART and cardiovascular disease. The management of risk factors for cardiovascular disease is expected to play an important role in the treatment of HIV infection.

Additional keywords: antiretroviral, cardiovascular disease, risk factors.


References


[1] Carr A,  Samaras K,  Thorisdottir A,  Kaufmann G,  Chisholm D,  Cooper D. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353 2093–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[2] Shahmanesh M,  Das S,  Stolinski M,  Shojaee-Moradie F,  Jackson NC,  Jefferson W, et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 2005; 90(2): 755–60.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[3] Badiou S,  Merle De Boever C,  Dupuy AM,  Baillat V,  Cristol JP,  Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003; 168(1): 107–13.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[4] Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118(Suppl 2): 23–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[5] Mary-Krause M,  Cotte L,  Simon A,  Partisani M,  Costagliola D,  . Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479–86.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[6] Iloeje U,  Yuan Y,  L’Italien G,  Mauskopf J,  Holmberg SD,  Moorman AC, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6(1): 37–44.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Currier JS,  Taylor A,  Boyd F,  Dezii CM,  Kawabata H,  Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33(4): 506–12.
| PubMed |

[8] Klein D,  Hurley LB,  Quesenberry CP,  Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30(5): 471–7.
| PubMed |

[9] El-Sadr W, Reiss P, De Wit S, D’Arminio Monforte A, Thiébaut R, Morfeldt L, et al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22–25 February 2005, Boston. Abstract 42.

[10] Bozzette SA,  Ake CF,  Tam HK,  Chang SW,  Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348 702–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[11] Sabin C, Morfeldt L, Friis-Møller N, Rickenbach M, Reiss P, D’Arminio Monforte A, et al. Changes over time in the use of antiretroviral therapy and risk factors for cardiovascular disease in the D:A:D Study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22–25 February 2005, Boston. Abstract 866.

[12] Stein JH,  Klein MA,  Bellehumeur JL,  McBride PE,  Wiebe DA,  Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104 257–62.
| PubMed |

[13] Maggi P,  Serio G,  Epifani G,  Fiorentino G,  Saracino A,  Fico C, et al. Premature lesions of the carotid vessels in HIV-1–infected patients treated with protease inhibitors. AIDS 2000; 14 F123–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[14] Thiébaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al. The changing face of cardiovascular risk in HIV-infected patients. ANRS Aquitaine Cohort, 2003. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, 22–25 February 2005, Boston. Abstract 871.

[15] Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005; 38(2): 115–23.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[16] Dressman J,  Kincer J,  Matveev SV,  Guo L,  Greenberg RN,  Guerin T, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent choesteryl ester accumulation in macrophages. J Clin Invest 2003; 111 389–97.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[17] Sutinen J,  Korsheninnikova E,  Funahashi T,  Matsuzawa Y,  Nyman T,  Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88(4): 1907–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[18] Tabib A,  Leroux C,  Mornex JF,  Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000; 11 41–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[19] Wilson PW,  Castelli WP,  Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987 May 29. 2005; 59(14): 91G–94G.


[20] Kamin DS,  Steven K,  Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19(7): 641–52.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[21] Johnson M,  Grinsztejn B,  Rodriguez C,  Coco J,  DeJesus E,  Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19(7): 685–94.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[22] Rodriguez-French A,  Boghossian J,  Gray GE,  Nadler JP,  Quinones AR,  Gladys E, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35(1): 22–32.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[23] Noor MA,  Seneviratne T,  Aweeka FT,  Lo J,  Schwarz J-M,  Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16 F1–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[24] Gallant JE,  Staszewski S,  Pozniak AL,  DeJesus E,  Suleiman JMAH,  Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292 191–201.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[25] Van der Valk M,  Kastelein JJ,  Murphy RL,  van Leth F,  Katlama C,  Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15 2407–14.
| Crossref | GoogleScholarGoogle Scholar | PubMed |